Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Myriad Genetics (MYGN) Revenue (2016 - 2026)

Myriad Genetics has reported Revenue over the past 17 years, most recently at $209.8 million for Q4 2025.

  • Quarterly Revenue changed 0.38% to $209.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $824.5 million through Dec 2025, down 1.56% year-over-year, with the annual reading at $824.5 million for FY2025, 1.56% down from the prior year.
  • Revenue was $209.8 million for Q4 2025 at Myriad Genetics, up from $205.7 million in the prior quarter.
  • Over five years, Revenue peaked at $213.3 million in Q3 2024 and troughed at $156.4 million in Q3 2022.
  • The 5-year median for Revenue is $190.6 million (2021), against an average of $189.2 million.
  • The largest YoY upside for Revenue was 103.22% in 2021 against a maximum downside of 46.36% in 2021.
  • A 5-year view of Revenue shows it stood at $160.8 million in 2021, then rose by 10.57% to $177.8 million in 2022, then increased by 10.57% to $196.6 million in 2023, then grew by 7.12% to $210.6 million in 2024, then fell by 0.38% to $209.8 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Revenue are $209.8 million (Q4 2025), $205.7 million (Q3 2025), and $213.1 million (Q2 2025).